UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 5.199

Sortiert nach

Immunogenicity of therapeutic recombinant immunotoxins

Immunological reviews, 2016-03, Vol.270 (1), p.152-164

2016

Volltextzugriff (PDF)

Critical Issues in the Development of Immunotoxins for Anticancer Therapy

Journal of pharmaceutical sciences, 2020-01, Vol.109 (1), p.104-115

2020

Volltextzugriff (PDF)

Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs

European journal of pharmacology, 2024-04, Vol.968, p.176408-176408, Article 176408

2024

Volltextzugriff (PDF)

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2012-07, Vol.109 (29), p.11782-11787

2012

Volltextzugriff (PDF)

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model

FEBS open bio, 2023-07, Vol.13 (7), p.1309-1319

2023

Volltextzugriff (PDF)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures

Proceedings of the National Academy of Sciences - PNAS, 2022-11, Vol.119 (48), p.e2214928119

2022

Volltextzugriff (PDF)

Intein-mediated cytoplasmic reconstitution of a split toxin enables selective cell ablation in mixed populations and tumor xenografts

Proceedings of the National Academy of Sciences - PNAS, 2020-09, Vol.117 (36), p.22090-22100

2020

Volltextzugriff (PDF)

Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion

International journal of molecular sciences, 2021-06, Vol.22 (12), p.6483

2021

Volltextzugriff (PDF)

Ribosome-Inactivating Proteins from Plants: A Historical Overview

Molecules, 2016-11, Vol.21 (12), p.1627

2016

Volltextzugriff (PDF)

A senolytic immunotoxin eliminates p16-positive T cells and ameliorates age-associated phenotypes of CD4+ T cells in a surface marker knock-in mouse

Experimental gerontology, 2023-04, Vol.174, p.112130, Article 112130

2023

Volltextzugriff (PDF)

A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

The FEBS journal, 2011-12, Vol.278 (23), p.4683-4700

2011

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

Journal of clinical oncology, 2010-04, Vol.28 (12), p.2085-2093

2010

Volltextzugriff (PDF)

Engineered Anti‐GPC3 Immunotoxin, HN3‐ABD‐T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention

Hepatology (Baltimore, Md.), 2020-05, Vol.71 (5), p.1696-1711

2020

Volltextzugriff (PDF)

Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine

Proceedings of the National Academy of Sciences - PNAS, 2020-03, Vol.117 (11), p.6086-6091

2020

Volltextzugriff (PDF)

Refined immunoRNases for the efficient targeting and selective killing of tumour cells: A novel strategy

Life sciences (1973), 2022-01, Vol.289, p.120222-120222, Article 120222

2022

Volltextzugriff (PDF)

Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation

Frontiers in immunology, 2020-06, Vol.11, p.1261

2020

Volltextzugriff (PDF)

Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial

Applied microbiology and biotechnology, 2017-04, Vol.101 (7), p.2747-2766

2017

Volltextzugriff (PDF)

Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy

Current pharmaceutical design, 2014-12, Vol.20 (42), p.6584

2014

Volltextzugriff (PDF)

Removing T-cell epitopes with computational protein design

Proceedings of the National Academy of Sciences - PNAS, 2014-06, Vol.111 (23), p.8577-8582

2014

Volltextzugriff (PDF)

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Blood, 2017-10, Vol.130 (14), p.1620-1627

2017

Volltextzugriff (PDF)

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

Cancer research (Chicago, Ill.), 2008-11, Vol.68 (22), p.9280-9290

2008

Volltextzugriff (PDF)

A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice

International journal of cancer, 2016-02, Vol.138 (4), p.1013-1023

2016

Volltextzugriff (PDF)

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

Proceedings of the National Academy of Sciences - PNAS, 2014-06, Vol.111 (23), p.8571-8576

2014

Volltextzugriff (PDF)

In vitro analysis of single chain variable fragment-based immunotoxins against Erythropoietin-producing hepatocellular A2 receptor overexpressed in breast cancer cells

Journal of immunological methods, 2024-08, p.113732, Article 113732

2024

Volltextzugriff (PDF)

Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells

Protein science, 2023-09, Vol.32 (9), p.e4741-n/a

2023

Volltextzugriff (PDF)

1 – 25 von 5.199

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.657)
Mit Volltextzugriff
(4.094)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.869)
Life Sciences & Biomedicine
(3.690)
Humans
(3.358)
Animals
(3.038)
Biological And Medical Sciences
(1.946)
Mice
(1.620)
Immunotoxins - Therapeutic Use
(1.531)
Medical Sciences
(1.457)
Immunotoxins - Pharmacology
(1.251)
Oncology
(1.251)
Female
(1.077)
Immunotoxins
(1.036)
Pharmacology. Drug Treatments
(972)
Male
(919)
Immunotoxin
(855)
Antibodies, Monoclonal - Therapeutic Use
(830)
Antineoplastic Agents
(815)
Immunotherapy
(723)
Rats
(675)
Ribosome Inactivating Proteins, Type 1
(643)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Immunogenicity of therapeutic recombinant immunotoxins

Critical Issues in the Development of Immunotoxins for Anticancer Therapy

Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures

Intein-mediated cytoplasmic reconstitution of a split toxin enables selective cell ablation in mixed populations and tumor xenografts

Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion

Ribosome-Inactivating Proteins from Plants: A Historical Overview

A senolytic immunotoxin eliminates p16-positive T cells and ameliorates age-associated phenotypes of CD4+ T cells in a surface marker knock-in mouse

A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

Engineered Anti‐GPC3 Immunotoxin, HN3‐ABD‐T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention

Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine

Refined immunoRNases for the efficient targeting and selective killing of tumour cells: A novel strategy

Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation

Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial

Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy

Removing T-cell epitopes with computational protein design

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

In vitro analysis of single chain variable fragment-based immunotoxins against Erythropoietin-producing hepatocellular A2 receptor overexpressed in breast cancer cells

Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells

Suchergebnisse filtern